This article provides a comprehensive analysis of gain-of-function (GOF) and loss-of-function (LOF) mutations within the STAT protein SH2 domain, a critical hotspot in oncology and immunology.
This article provides a comprehensive resource for researchers and drug development professionals investigating how mutations in the Src Homology 2 (SH2) domain impact Signal Transducer and Activator of Transcription (STAT)...
This article provides a comprehensive comparative analysis of the Src Homology 2 (SH2) domains found in STAT and Src-family proteins, two classes of proteins central to cellular signaling.
The development of selective inhibitors for STAT (Signal Transducer and Activator of Transcription) SH2 domains represents a promising therapeutic strategy for cancers and inflammatory diseases.
The development of specific STAT SH2 domain inhibitors represents a promising therapeutic strategy for cancers and inflammatory diseases.
This article provides a comprehensive comparison for researchers and drug development professionals on two primary strategies for inhibiting SH2 domain-mediated protein-protein interactions: small molecules and peptidomimetics.
This review provides a comprehensive comparative analysis of the Src Homology 2 (SH2) domains of STAT1 and STAT3, transcription factors critical in immunity, inflammation, and cancer.
Constitutive activation of the JAK-STAT pathway is a hallmark of numerous cancers and autoimmune diseases, driving the development of targeted inhibitors.
Targeting Src Homology 2 (SH2) domains represents a promising therapeutic strategy for modulating dysregulated cell signaling in cancer and other diseases.
This article provides a comprehensive analysis of rapid off-rates in SH2 domain-phosphopeptide interactions, a critical feature for ensuring dynamic and specific cellular signaling.